The goal of this study was to investigate the prognostic significance of FOXC1 expression in early-stage TNBC patients treated with standard chemotherapy and the effect of FOXC1 overexpression on the chemotherapeutic response in triple-negative breast cancer patients. Here, FOXC1 is linked to triple-negative breast carcinoma.